Generic Name and Formulations:
Droperidol 2.5mg/mL; soln for IV or IM inj.
Various generic manufacturers
Indications for Droperidol:
To reduce incidence of nausea and vomiting associated with surgical and diagnostic procedures.
Max initial dose: 2.5mg IM or slow IV; may give additional 1.25mg doses to achieve desired effect.
<2yrs: not recommended. ≥2yrs: max initial dose: 0.1mg/kg.
QT prolongation (including congenital long QT syndrome).
Perform ECG prior to administration to determine if prolonged QT interval present; if prolonged, do not administer unless treatment outweighs risks; if treating, monitor for arrhythmias: perform ECG prior to treatment and 2–3hrs after completion. Risk factors for QT prolongation: CHF, bradycardia, cardiac hypertrophy, hypokalemia, hypomagnesemia, >65yrs, alcohol abuse. Pheochromocytoma. Hepatic or renal impairment. Elderly. Debilitated. Critically ill. Labor & delivery: not recommended. Pregnancy (Cat.C). Nursing mothers.
Risk of QT prolongation with concomitant Class I and III antiarrhythmics, MAOIs, antimalarials, calcium channel blockers, benzodiazepines, volatile anesthetics, IV opiates, other drugs that prolong QT interval. Caution with drugs that induce hypokalemia, hypomagnesemia (eg, diuretics, laxatives). Additive effects with CNS depressants (eg, barbiturates, tranquilizers, opioids, general anesthetics). Possible hypertension with concomitant fentanyl citrate inj.
Hypotension, tachycardia, dysphoria, drowsiness, restlessness, hyperactivity, anxiety, QT prolonation, torsade de pointes, cardiac arrest, ventricular tachycardia, neuroleptic malignant syndrome, post-op hallucinatory episodes.
Formerly known under the brand name Inapsine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline